定义接受立体定向体部放疗的早期非小细胞肺癌患者最佳合并症测量指标
本研究纳入548例接受SBRT的I期非小细胞肺癌患者,比较5种指标对总生存的预后价值。结果显示年龄调整Charlson合并症指数(CCIa)预测OS最佳,二分类CCIa(≥6)可用于未来SBRT与OS的比较,未发现中位生存不足1年的队列。
要点
- CCIa是接受SBRT的I期非小细胞肺癌患者OS的最佳预后指标。
- CCIa≥6时死亡风险比为1.47(95%CI 1.20-1.80)。
- 二分类未显著损失预后效能,CCIa≥6可用于未来比较。
核心结论
- CCIa在所有模型中均为OS的最佳指标,二分类未损失预后效能。
- CCIa二分类(≥6)可用于未来SBRT与OS的比较。
- 未发现中位生存不足1年的队列,因此不能认定治疗无效。
研究设计与样本
- 分析548例接受SBRT的I期非小细胞肺癌患者。
- 使用对数秩检验将患者按各指标分为OS高危和低危组。
- 通过赤池信息准则和Vuong检验比较连续模型与二分类模型。
- 采用多变量Cox回归结合人口学信息确定各指标连续和二分类版本的独立预后价值。
主要发现
- 年龄、ECOG状态、ACE-27、CCI、CCIa的最佳截点分别为≥75岁、≥1、≥3、≥3、≥6,死亡风险比分别为1.23(95%CI 1.00-1.50)、1.66(1.28-2.15)、1.37(1.12-1.67)、1.43(1.17-1.76)、1.47(1.20-1.80)。
- 各指标预后效能无显著差异,但CCIa预测OS最佳。
- CCIa将患者分为3组,评分≤5、6-7、≥8的中位OS分别为42个月、33个月、23个月。
关键数值与推荐
- CCIa评分≤5、6-7、≥8对应的中位OS分别为42个月、33个月、23个月。
- CCIa≥6时死亡风险比为1.47(95%CI 1.20-1.80)。
临床怎么用
- 作者认为CCIa二分类(≥6)可用于未来SBRT与OS的比较。
- 原文未据此给出其他临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Comparison of overall survival (OS) between stereotactic body radiation therapy (SBRT) and other treatments for early-stage non-small cell lung cancer is confounded by differences in age, performance status, and medical comorbidity. We sought to define the most robust measurement for this population among 5 indices: age, Eastern Cooperative Oncology Group performance status, Adult Comorbidity Evaluation 27, Charlson Comorbidity Index (CCI), and age-adjusted CCI (CCIa). METHODS AND MATERIALS: A total of 548 patients with stage I non-small cell lung cancer treated with SBRT were analyzed. Patients were divided into high- and low-risk groups for OS for each index using the log-rank test. Continuous and dichotomized models were compared via Akaike information criterion and the Vuong test. Multivariate Cox regression modeling was used with demographic information to determine the independent prognostic value of the continuous and dichotomized versions of the indices. The best was used to stratify the patients into as many significantly different cohorts as possible. RESULTS: Optimal cut-points between high-risk and low-risk OS groups for age, Eastern Cooperative Oncology Group status, Adult Comorbidity Evaluation 27, CCI, and CCIa were ≥75 years, ≥1, ≥3, ≥3, and ≥6 with hazard ratios for death of 1.23 (95% confidence interval, 1.00-1.50), 1.66 (1.28-2.15), 1.37 (1.12-1.67), 1.43 (1.17-1.76), and 1.47 (1.20-1.80), respectively. Dichotomizing did not result in a significant loss of prognostic power. Although there was no significant difference in prognostic power among the indices, CCIa best predicted OS. CCIa divided the patients into 3 cohorts with median OS of 42 months, 33 months, and 23 months for scores of ≤5, 6 to 7, and ≥8, respectively. CONCLUSIONS: CCIa was the best indicator of OS in every model employed with no loss of prognostic power with dichotomization. Dichotomization of CCIa (≥6) could be implemented in future comparisons of SBRT with OS. No cohort could be identified with a median survival of less than a year, for which treatment could be deemed futile.
引用
- DeWees TA, Nikitas J, Rehman S, et al. Defining Optimal Comorbidity Measures for Patients With Early-Stage Non-small cell lung cancer Treated With Stereotactic Body Radiation Therapy. Pract Radiat Oncol. 2018. PMID: 30244094. doi:10.1016/j.prro.2018.09.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。